4,901 trials
Healthy Volunteers
Primary: Number of Participants Who Tolerated All Initiated HYQVIA Infusion — 7; 8; 8; 9 Participants
Healthy Participants
Primary: Period 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Sotorasib — 4170; 4340 ng/mL
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of Midazolam — 25.3; 28.8 ng/mL
HIV-1 Infection
Primary: Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose (AUC0-24) of R-Methadone — 61.9; 63.9 ng*h/mL/mg
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) — 238.6; 341.3; 3831; 4891 pg/mL
Healthy Volunteers
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 2; 1; 0; 1 Participants
Actinic Porokeratosis
Primary: Measurement of Treatment Efficacy Determined by DSAP-GASI Score (Disseminated Actinic Porokeratosis General Assessment Severity Index) — 50.0; 51.4 Percent decrease in…
Lymphoma · Metastatic Malignant Solid Neoplasm · Metastatic Melanoma
Primary: Maximum Tolerated Dose (MTD))/Recommended Phase 2 Dose of Trigriluzole — 420 mg
HIV Infections
Primary: Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC[0-t]) of GSK3640254 — 102400 Hours*nanograms per milliliter
Acute Kidney Injury (AKI)
Primary: Frequency of Adverse Events (AEs) — 6; 1; 3; 1 Participants
Healthy Volunteers
Primary: Area Under the Concentration Versus Time Curve (AUC0-∞) for Rivaroxaban — 1049.19; 2274.3; 2226.38 hr*ng/ml
Obesity
Primary: Area Under the Plasma Concentration-time Profile From Time 0 to Last Quantifiable Concentration (AUClast) of Rosuvastatin in Periods 1, 4 and 7 — 35.17; 72.15; 100.90…
Influenza
Primary: Number and Percentage of Participants With Symptomatic Influenza Virus Infection After Challenge. — 4; 5; 28; 0 Participants
Healthy
Primary: DASS-21 — 2.9; 2.7; 4.5 units on a scale
Neoplasms
Primary: The Maximum Tolerated Dose (MTD)/Optimal Biological Dose (OBD) of BI 905681 — NA milligram/kilogram